Perioperative factor concentrate therapy

British Journal of Anaesthesia

Volumn 111, Issue SUPPL.1, 2013, Pages

  Tanaka, K A ^a   Esper, S ^a   Bolliger, D ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

antithrombin concentrate; coagulation monitoring; cryoprecipitate; fibrinogen concentrate; fresh frozen plasma; prothrombin complex concentrate

Indexed keywords

ANTITHROMBIN III; ANTITHROMBIN III CONCENTRATE; APIXABAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; EDOXABAN; FIBRINOGEN; FIBRINOGEN CONCENTRATE; HAEMOCOMPLETTAN; HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN COMPLEX; RECOMBINANT ANTITHROMBIN III; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

AFIBRINOGENEMIA; ANAPHYLAXIS; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLOOD COMPONENT; CRYOPRECIPITATE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; FEVER; FIBRINOGEN DEFECT; HEADACHE; HEART INFARCTION; HEMARTHROSIS; HEMATOMA; HEMOPHILIA B; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOFIBRINOGENEMIA; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; LUNG EMBOLISM; NONHUMAN; OPERATIVE BLOOD LOSS; PERIOPERATIVE PERIOD; PLASMA TRANSFUSION; POINT OF CARE TESTING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAFETY; THROMBOEMBOLISM; THROMBOSIS;

EID: 84890627453     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet380     Document Type: Article

References (137)

1. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009; 108: 1433-46
2. Tanaka KA, Bolliger D, Vadlamudi R, Nimmo A. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth 2012; 26: 1083-93
3. Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010; 113: 1205-19
4. Dutton RP. Haemostatic resuscitation. Br J Anaesth 2012; 109 (Suppl. 1): i39-46
5. Schochl H, Grassetto A, SchlimpCJ.Managementofhemorrhagein trauma. J Cardiothorac Vasc Anesth 2013; 27: S35-43
6. Gorlinger K, Shore-Lesserson L, Dirkmann D, Hanke A, Rahe-Meyer N, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth 2013; 27: S20-34
7. Nuttall GA, Oliver WC, Ereth MH, Santrach PJ. Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 815-23
8. Nuttall GA. Goal-directed therapy: evidence and outcome. J Cardiothorac Vasc Anesth 2013; 27: S6-8
9. Tanaka KA, Bader SO, Sturgill EL. Diagnosis of perioperative coagulopathy- plasma versus whole blood testing. J Cardiothorac Vasc Anesth 2013; 27: S9-15
10. Hannon T. Trauma blood management: avoiding the collateral damage of trauma resuscitation protocols. Hematology Am Soc Hematol Educ Program 2010; 1: 463-4
11. Brooker M. Registry of Clotting Factor Concentrate, 9th edn. Montreal:World Federation of Hemophilia, 2012
12. Kcentra, Prothrombin Complex Concentrate (Human). Prescribing Information. Marburg, Germany: CSL Behring, April 2013
13. Downes KA, Wilson E, Yomtovian R, Sarode R. Serial measurement of clotting factors in thawed plasma stored for 5 days. Transfusion 2001; 41: 570
14. Theusinger OM, Baulig W, Seifert B, Emmert MY, Spahn DR, Asmis LM. Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma. Br J Anaesth 2011; 106: 505-11
15. ChowdaryP, SaaymanAG,Paulus U, FindlayGP,CollinsPW. Efficacy of standard dose and30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125: 69-73
16. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012; 52: 160-5
17. Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation management- fresh frozen plasma. Best Pract Res Clin Anaesthesiol 2010; 24: 51-64
18. Chapman CE, StainsbyD, Jones H, et al. Tenyears ofhemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009; 49: 440-52
19. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012; 119: 1757-67
20. Nielsen HJ, Reimert C, Pedersen AN, et al. Leucocyte-derived bioactive substances in fresh frozen plasma. Br J Anaesth 1997; 78: 548-52
21. Schneider SO, Rensing H, Graber S, et al. Impact of platelets and freshfrozenplasmain contrastto redcell concentrateonunstimulated and stimulated cytokine release in an in vitro model of transfusion. Scand J Immunol 2009; 70: 101-5
22. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to redblood cell ratios improvesoutcomein466massively transfused civilian trauma patients. Ann Surg 2008; 248: 447-58
23. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA. Haemodilution-induced profibrinolytic state is mitigated by freshfrozen plasma: implications for early haemostatic intervention in massive haemorrhage. Br J Anaesth 2010; 104: 318-25
24. Kozar RA, Peng Z, Zhang R, et al. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg 2011; 112: 1289-95
25. Watson GA, Sperry JL, Rosengart MR, et al. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma 2009; 67: 221-7
26. Ho AM, Dion PW, Yeung JH, et al. Prevalence of survivor bias in observational studies on fresh frozen plasma:erythrocyte ratios in trauma requiring massive transfusion. Anesthesiology 2012; 116: 716-28
27. Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37: 151-5
28. Mayer SA, Rincon F. Ultra-earlyhemostatic therapy foracute intracerebral hemorrhage. Semin Hematol 2006; 43: S70-6
29. Chandler WL, Ferrell C, Trimble S, Moody S. Development of a rapid emergency hemorrhage panel. Transfusion 2010; 50: 2547-52
30. Mehr CR, Gupta R, von Recklinghausen FM, Szczepiorkowski ZM, Dunbar NM. Balancing risk and benefit: maintenance of a thawed Group A plasma inventory for trauma patients requiring massive transfusion. J Trauma Acute Care Surg 2013; 74: 1425-31
31. Heindl B, Delorenzo C, Spannagl M. High dose fibrinogen administration for acute therapy of coagulopathy during massive perioperative transfusion. Anaesthesist 2005; 54: 787-90
32. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106: 1366-75
33. Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 2012; 26: 1-13
34. Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009; 7: 795-802
35. Schochl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14: R55
36. Gorlinger K, DirkmannD,HankeAA, et al. First-linetherapywith coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, singlecenter cohort study. Anesthesiology 2011; 115: 1179-91
37. Gorlinger K, Dirkmann D, Solomon C, Hanke AA. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability. Br J Anaesth 2013; 110: 222-30
38. Larsen OH, Fenger-Eriksen C, Christiansen K, Ingerslev J, Sorensen B. Diagnostic performance and therapeutic consequence of thromboelastometry activated by kaolin versus a panel of specific reagents. Anesthesiology 2011; 115: 294-302
39. Solomon C, Sorensen B, Hochleitner G, Kashuk J, Ranucci M, Schochl H. Comparison of whole blood fibrin-based clot tests in thrombelastography and thromboelastometry. Anesth Analg 2012; 114: 721-30
40. Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep 2004; 3: 324-30
41. Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology Am Soc Hematol Educ Program 2007: 179-86
42. Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg 2012; 256: 476-86
43. Rumph B, Bolliger D, Narang N, et al. In vitro comparative study of hemostatic components in warfarin-treated and fibrinogendeficient plasma. J Cardiothorac Vasc Anesth 2010; 24: 408-12
44. Levy JH, Szlam F, TanakaKA, Sniecienski RM. Fibrinogenandhemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114: 261-74
45. Blomback B. Travels with fibrinogen. J Thromb Haemost 2006; 4: 1653-60
46. Kasper CK. Judith Graham Pool and the discovery of cryoprecipitate. Haemophilia 2012; 18: 833-5
47. Caudill JS, Nichols WL, Plumhoff EA, et al. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion 2009; 49: 765-70
48. Weber CF, Gorlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117: 531-47
49. Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010; 251: 217-28
50. RiaSTAP, Fibrinogen Concentrate (Human). Prescribing Information. CSL Behring: Marburg, Germany, December 2011
51. Bolliger D, SreeramG, Duncan A, et al. Prophylactic use of factor IX concentrate inaJehovah'sWitness patient.AnnThorac Surg 2009; 88: 1666-8
52. Solomon C, Pichlmaier U, Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104: 555-62
53. Theodoulou A, Berryman J, Nathwani A, Scully M. Comparison of cryoprecipitate with fibrinogen concentrate for acquired hypofibrinogenaemia. Transfus Apher Sci 2012; 46: 159-62
54. Sorensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149: 834-43
55. Groner A. Reply: Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2008; 93: e24-6; author reply e27
56. Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997; 78: 611-6
57. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-92
58. MosessonMW.UpdateonantithrombinI (fibrin). ThrombHaemost 2007; 98: 105-8
59. Ariens RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11 (Suppl. 1): 294-305
60. Ogawa S, Ohnishi T, Hosokawa K, Szlam F, Chen EP, Tanaka KA. Haemodilution-induced changes in coagulation and effects of haemostatic components under flow conditions. Br J Anaesth 2013 Advance Access published on20 June 2013, doi:10.1093/ bja/aet229
61. Hathcock JJ, Nemerson Y. Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa. Blood 2004; 104: 123-7
62. Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9: 1687-704
63. Kozek-Langenecker SA, Afshari A, AlbaladejoP, et al.Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382
64. Rahe-MeyerN,SolomonC, HankeA, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013; 118: 40-50
65. SolomonC,CadamuroJ, Ziegler B, et al.Acomparisonof fibrinogen measurement methods with fibrin clot elasticity assessed by thromboelastometry, before and after administration of fibrinogen concentrate in cardiac surgery patients. Transfusion 2011; 51: 1695-706
66. HaasT, Fries D,Velik-Salchner C,Oswald E, InnerhoferP. Fibrinogen in craniosynostosis surgery. Anesth Analg 2008; 106: 725-31, table of contents
67. Girdauskas E, Kempfert J, Kuntze T, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg 2010; 140: 1117-24 e2
68. Fassl J,Matt P, Eckstein F, et al. Transfusion of allogeneic blood products in proximal aortic surgery with hyopthermic circulatory arrest: effects of thromboelastometry-guided transfusion management. J Cardiothorac Vasc Anesth 2013, doi:10.1053/ j.jvca.2013.02.009 (e-pub ahead of print)
69. OgawaS, Szlam F, Bolliger D, Nishimura T, Chen EP, Tanaka KA. The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. Anesth Analg 2012; 115: 16-21
70. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360-5
71. Bilecen S, Peelen LM, Kalkman CJ, Spanjersberg AJ, Moons KG, Nierich AP. Fibrinogen concentrate therapy in complex cardiac surgery. J Cardiothorac Vasc Anesth 2013; 27: 12-7
72. Tanaka KA, Egan K, Szlam F, et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion 2013, doi:10.1111/trf.12248 (e-pub ahead of print)
73. Korte WC, Szadkowski C, Gahler A, et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110: 239-45
74. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after majortrauma:differential diagnosis of lysis patternsandprognostic value of thrombelastometry. J Trauma 2009; 67: 125-31
75. Danes AF, Cuenca LG, Bueno SR, Mendarte Barrenechea L, Ronsano JB. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008; 94: 221-6
76. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med 2008; 18: 151-7
77. Gorlinger K, Fries D, Dirkmann D, Weber CF, Hanke AA, Schochl H. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus Med Hemother 2012; 39: 104-13
78. Santhosh J. Cross-sectional guidelines for therapy with blood components and plasma derivatives: Chapter7 Procoagulators. Transfus Med Hemother 2009; 36: 419-36
79. Dickneite G, Pragst I, Joch C, Bergman GE. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagul Fibrinolysis 2009; 20: 535-40
80. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439-48
81. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care 2011; 15: 201
82. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28: 3-5
83. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e44-88S
84. Levy JH, TanakaKA, DietrichW. Perioperativehemostaticmanagement of patients treated with vitamin K antagonists. Anesthesiology 2008; 109: 918-26
85. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121: 9-16
86. Pabinger I, BrennerB, Kalina U,KnaubS,NagyA, OstermannH. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-31
87. Sarode R, Rawal A, Lee R, Shen YM, Frenkel EP. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Haematol 2005; 132: 604-7
88. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due towarfarin overdose. Transfusion 2009; 49: 1171-7
89. Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 2008; 122: 117-23
90. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory studyonthe reversal ofwarfarin with rFVIIa inhealthy subjects. Blood 2010; 116: 693-701
91. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152-84S.
92. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10: 1478-85
93. Wojcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009; 2: 217-25
94. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-800
95. Tanaka KA, Bolliger D. On the reversal of neworal anti-coagulants: can we simply extrapolate data from the animal models to humans? Br J Anaesth 2013; 110: 329-32
96. Sarode R, Milling TJ Jr., Refaai MA, et al. Efficacy and safety of a four-factor prothrombincomplexconcentrate(4F-PCC) inpatients onvitaminKantagonists presenting with major bleeding: arandomized, plasma-controlled, phase IIIb study. Circulation 2013, doi:10.1161/ CIRCULATIONAHA.113.002283 (e-pub ahead of print)
97. Lance MD, Ninivaggi M, Schols SE, et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sang 2012; 103: 25-34
98. Bolliger D, Tanaka A. Roles of thrombelastography and thromboelastometry for the patient blood management in cardiac surgery. Transfus Med Rev 2013, doi:10.1016/j.tmrv.2013.08.004 (e-pub ahead of print)
99. Gorlinger K. Coagulation management during liver transplantation. Hamostaseologie 2006; 26: S64-76
100. Rugeri L, Levrat A,David JS, et al. Diagnosis of earlycoagulationabnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5: 289-95
101. Ogawa S, Szlam F, Chen EP, et al. A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion 2012; 52: 14-22
102. Nascimento B, Al Mahoos M, Callum J, et al. Vitamin K-dependent coagulation factor deficiency in trauma: a comparative analysis between international normalized ratio and thromboelastography. Transfusion 2012; 52: 7-13
103. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: 312-9
104. Johansson PI, Stensballe J. Effect of haemostatic control resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sang 2009; 96: 111-8
105. Majeed A, Eelde A, Agren A, Schulman S, Holmstrom M. Thromboembolic safetyand efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res 2012; 129: 146-51
106. Hanke AA, Joch C, Gorlinger K. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. Br J Anaesth 2013; 110: 764-72
107. GrottkeO,Braunschweig T, SpronkHM,et al. Increasingconcentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood 2011; 118: 1943-51
108. Bucciarelli P, Passamonti SM, Biguzzi E, et al. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J Thromb Haemost 2012; 10: 1783-91
109. Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg 2008; 85: 2153-60
110. FinleyA,GreenbergC.Reviewarticle: heparinsensitivityandresistance: management during cardiopulmonary bypass. Anesth Analg 2013; 116: 1210-22
111. LehmanCM, Rettmann JA,Wilson LW, Markewitz BA. Comparative performance of three anti-factorXaheparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin. Am J Clin Pathol 2006; 126: 416-21
112. Fukuda T, Kamisato C, Honda Y, et al. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin. Thromb Res 2013; 131: 540-6
113. Thrombate III, Antithrombin III (Human). Prescribing Information. Research Triangle Park, NC: Grifols Therapeutics, October 2012
114. ATryn, Antithrombin (Recombinant). Prescribing Information. Framingham, MA: GTC Biotherapeutics, November 2010
115. Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thromb Haemost 2009; 101: 806-12
116. Levy JH,Weisinger A, Ziomek CA, Echelard Y. Recombinant antithrombin: production and role in cardiovascular disorder. Semin Thromb Hemost 2001; 27: 405-16
117. Ranucci M, IsgroG,Cazzaniga A, SoroG, Menicanti L, Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999; 14: 437-42
118. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70: 873-7
119. Ranucci M, Isgro G, Cazzaniga A, et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199-204
120. Sabbagh AH, Chung GK, Shuttleworth P, Applegate BJ, GabrhelW. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. Ann Thorac Surg 1984; 37: 466-8
121. Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102: 276-84
122. AvidanMS, Levy JH, van Aken H, et al. Recombinant human antithrombinIII restoresheparin responsivenessanddecreasesactivation ofcoagulationinheparin- resistant patients duringcardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130: 107-13
123. Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90: 1076-9
124. Ranucci M, Baryshnikova E, Crapelli GB, Woodward MK, Paez A, Pelissero G. Preoperative antithrombin supplementation in cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 2013; 145: 1393-9
125. Ogawa S, Richardson JE, Sakai T, Ide M, Tanaka KA. High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass. J Anesth 2012; 26: 9-19
126. Langley PG, Hughes RD, Forbes A, Keays R, Williams R. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol 1993; 17: 326-31
127. Kawanaka H, Akahoshi T, Kinjo N, et al. Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. Ann Surg 2010; 251: 76-83
128. Waydhas C, Nast-Kolb D, Gippner-Steppert C, et al. High-dose antithrombin III treatment of severely injured patients: results of a prospective study. J Trauma 1998; 45: 931-40
129. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286: 1869-78
130. Gorlinger K, Dirkmann D, Hanke AA. Potential value of transfusion protocols in cardiac surgery. Curr Opin Anaesthesiol 2013; 26: 230-43
131. TanakaKA,KorDJ.Emerginghaemostaticagentsandpatient blood management. Best Pract Res Clin Anaesthesiol 2013; 27: 141-60
132. Gombotz H. Patient blood management: a patient-orientated approach to blood replacement with the goal of reducing anemia, blood loss and the need for blood transfusion in elective surgery. Transfus Med Hemother 2012; 39: 67-72
133. Shander A, VanAken H, Colomina MJ, et al. Patient blood management in Europe. Br J Anaesth 2012; 109: 55-68
134. Holcomb JB, Del Junco DJ, Fox EE, et al. The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg 2013; 148: 127-36
135. Ranucci M. Fibrinogen supplementation in cardiac surgery: where are we now and where are we going? J Cardiothorac Vasc Anesth 2013; 27: 1-4
136. Shakur H, Elbourne D, Gulmezoglu M, et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials 2010; 11: 40
137. Dewan Y, Komolafe EO, Mejia-Mantilla JH, Perel P, Roberts I, Shakur H. CRASH-3-tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials 2012; 13: 87